Cargando…

Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling

INTRODUCTION: Castration‐resistant prostate cancer (CRPC) remains dependent on androgen receptor (AR) signalling, which is largely driven by conversion of adrenal androgen precursors lasting after castration. Abiraterone, an inhibitor of the steroidogenic enzyme CYP17A1, has been demonstrated to red...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moll, J. Matthijs, Hofland, Johannes, Teubel, Wilma J., de Ridder, Corina M. A., Taylor, Angela E., Graeser, Ralph, Arlt, Wiebke, Jenster, Guido W., van Weerden, Wytske M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306678/ https://www.ncbi.nlm.nih.gov/pubmed/35037287 http://dx.doi.org/10.1002/pros.24297

Ejemplares similares

A bypass mechanism of abiraterone‐resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling
por: Moll, Jan M., et al.
Publicado: (2019)

Cell Line Characteristics Predict Subsequent Resistance to Androgen Receptor-Targeted Agents (ARTA) in Preclinical Models of Prostate Cancer
por: Moll, Jan Matthijs, et al.
Publicado: (2022)

Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling
por: Van Hemelryk, Annelies, et al.
Publicado: (2022)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models
por: Marques, Rute B., et al.
Publicado: (2010)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines
por: Marques, Rute B., et al.
Publicado: (2011)

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer
por: Liu, Chengfei, et al.
Publicado: (2016)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
por: Pak, Sahyun, et al.
Publicado: (2022)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013)

Modified-Release and Conventional Glucocorticoids and Diurnal Androgen Excretion in Congenital Adrenal Hyperplasia
por: Jones, Christopher M., et al.
Publicado: (2016)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer: A Phase II Trial
por: Locati, Laura D., et al.
Publicado: (2021)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
por: Rehman, Yasser, et al.
Publicado: (2012)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration
por: Snaterse, Gido, et al.
Publicado: (2021)

Involvement of the Androgen and Glucocorticoid Receptors in Bladder Cancer
por: McBeth, Lucien, et al.
Publicado: (2015)

Comparing the rules of engagement of androgen and glucocorticoid receptors
por: Claessens, Frank, et al.
Publicado: (2017)

SAT-LB002 Steroid Metabolome Analysis Reveals 11-Ketotestosterone as the Most Abundant Androgen in Castration-Resistant Prostate Cancer Patients on Second-Line Therapies
por: Snaterse, Gido, et al.
Publicado: (2019)

Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
por: Sekine, Yoshitaka, et al.
Publicado: (2021)

PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells
por: Liu, Wei, et al.
Publicado: (2021)

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
por: Ban, Fuqiang, et al.
Publicado: (2021)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Dominant-Negative Androgen Receptor Inhibition of Intracrine Androgen-Dependent Growth of Castration-Recurrent Prostate Cancer
por: Titus, Mark A., et al.
Publicado: (2012)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
por: Pezaro, C, et al.
Publicado: (2013)

Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor
por: Hu, Zengchun, et al.
Publicado: (2021)

Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens
por: Dart, D. A., et al.
Publicado: (2011)

Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer
por: van Leenders, Geert J. L. H., et al.
Publicado: (2011)

Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription
por: Jia, Lin, et al.
Publicado: (2018)

Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015)

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer
por: Pollock, Julie A., et al.
Publicado: (2016)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020)

Androgen regulation of the androgen receptor coregulators
por: Urbanucci, Alfonso, et al.
Publicado: (2008)

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nc3bt5kfibdt14j2m6p0gs35co